Shanghai ZJ Bio-Tech Co. Ltd. A (688317) - Total Liabilities
Based on the latest financial reports, Shanghai ZJ Bio-Tech Co. Ltd. A (688317) has total liabilities worth CN¥404.13 Million CNY (≈ $59.14 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai ZJ Bio-Tech Co. Ltd. A - Total Liabilities Trend (2013–2025)
This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See 688317 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Shanghai ZJ Bio-Tech Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Shanghai ZJ Bio-Tech Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan Mendale Hometextile Co Ltd
SHE:002397
|
China | CN¥1.11 Billion |
|
Fenerbahce Futbol AS
IS:FENER
|
Turkey | TL19.22 Billion |
|
Traffic Control Technology Co Ltd
SHG:688015
|
China | CN¥3.67 Billion |
|
Mekonomen AB
ST:MEKO
|
Sweden | Skr11.51 Billion |
|
Claritev Corporation
NYSE:CTEV
|
USA | $5.07 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥247.20 Million |
|
Ipd Group Ltd
AU:IPG
|
Australia | AU$172.83 Million |
|
DINGDONG CAYMAN 2ADR/3 A
F:945
|
Germany | €5.84 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Shanghai ZJ Bio-Tech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai ZJ Bio-Tech Co. Ltd. A (688317) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 25.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai ZJ Bio-Tech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)
The table below shows the annual total liabilities of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥414.95 Million ≈ $60.72 Million |
+171.10% |
| 2024-12-31 | CN¥153.06 Million ≈ $22.40 Million |
-38.59% |
| 2023-12-31 | CN¥249.25 Million ≈ $36.47 Million |
-54.13% |
| 2022-12-31 | CN¥543.44 Million ≈ $79.52 Million |
+27.19% |
| 2021-12-31 | CN¥427.27 Million ≈ $62.52 Million |
+2.47% |
| 2020-12-31 | CN¥416.97 Million ≈ $61.02 Million |
+494.94% |
| 2019-12-31 | CN¥70.09 Million ≈ $10.26 Million |
+49.20% |
| 2018-12-31 | CN¥46.98 Million ≈ $6.87 Million |
+8.18% |
| 2017-12-31 | CN¥43.42 Million ≈ $6.35 Million |
+1.78% |
| 2016-12-31 | CN¥42.66 Million ≈ $6.24 Million |
-16.06% |
| 2015-12-31 | CN¥50.82 Million ≈ $7.44 Million |
-43.07% |
| 2014-12-31 | CN¥89.28 Million ≈ $13.06 Million |
+72.51% |
| 2013-12-31 | CN¥51.75 Million ≈ $7.57 Million |
-- |
About Shanghai ZJ Bio-Tech Co. Ltd. A
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. It offers nucleic acid and real-time PCR kits, as well as consumables. The company was founded in 2005 and is based in Shanghai, China.